• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Integrating Models to Quantify Environment-Mediated Drug Resistance.整合模型以量化环境介导的耐药性。
Cancer Res. 2017 Oct 1;77(19):5409-5418. doi: 10.1158/0008-5472.CAN-17-0835. Epub 2017 Jul 28.
2
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.通过使用ganetespib靶向抑制Hsp90克服黑色素瘤中获得性BRAF抑制剂耐药性。
Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.
3
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.PRIMA-1(Met)(APR-246)介导的p53激活使(V600E/K)BRAF黑色素瘤对维莫非尼敏感。
Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.
4
[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].[BRAFV600 突变转移性黑色素瘤中致癌副作用及对 BRAF 抑制剂耐药的细胞与分子机制:知识现状]
Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31.
5
Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling.长链非编码 RNA TSLNC8 的下调通过与 PP1α 结合重新激活 MAPK 信号通路促进黑色素瘤对 BRAF 抑制剂 PLX4720 的耐药性。
J Cancer Res Clin Oncol. 2021 Mar;147(3):767-777. doi: 10.1007/s00432-020-03484-4. Epub 2021 Jan 3.
6
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.一种新型水溶性丝裂原活化蛋白激酶(MAPK)激活剂在对BRAF抑制剂威罗菲尼耐药的黑色素瘤细胞中发挥抗肿瘤活性。
Biochem Pharmacol. 2015 May 1;95(1):16-27. doi: 10.1016/j.bcp.2015.03.004. Epub 2015 Mar 17.
7
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.靶向 ER 应激诱导的自噬克服黑色素瘤中 BRAF 抑制剂耐药性。
J Clin Invest. 2014 Mar;124(3):1406-17. doi: 10.1172/JCI70454. Epub 2014 Feb 24.
8
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.针对不同ErbB3表面表位的抗体组合可防止黑色素瘤对BRAF/MEK抑制剂产生耐药性。
Oncotarget. 2015 Sep 22;6(28):24823-41. doi: 10.18632/oncotarget.4485.
9
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.由β-连环蛋白和信号转导与转录激活因子3组成的信号枢纽减弱了BRAF抑制剂的疗效并介导对维莫非尼的获得性耐药。
EBioMedicine. 2016 Jun;8:132-149. doi: 10.1016/j.ebiom.2016.04.037. Epub 2016 May 1.
10
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.在黑色素瘤中建立vemurafenib 耐药模型揭示了一种预防耐药的策略。
Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9.

引用本文的文献

1
The role of environmentally mediated drug resistance in facilitating the spatial distribution of residual disease.环境介导的耐药性在促进残留疾病空间分布中的作用。
Commun Biol. 2025 Aug 9;8(1):1189. doi: 10.1038/s42003-025-08585-9.
2
Modeling critical dosing strategies for stromal-induced resistance to cancer therapy.构建基质诱导的癌症治疗耐药性的关键给药策略模型。
NPJ Syst Biol Appl. 2025 Feb 6;11(1):16. doi: 10.1038/s41540-025-00495-0.
3
Dissecting the Spatially Restricted Effects of Microenvironment-Mediated Resistance on Targeted Therapy Responses.剖析微环境介导的耐药性对靶向治疗反应的空间限制效应。
Cancers (Basel). 2024 Jun 29;16(13):2405. doi: 10.3390/cancers16132405.
4
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.骨生态系统促进多发性骨髓瘤复发和异质性耐药疾病的演变。
Nat Commun. 2024 Mar 19;15(1):2458. doi: 10.1038/s41467-024-46594-0.
5
Localized immune surveillance of primary melanoma in the skin deciphered through executable modeling.通过可执行建模解析皮肤原发性黑素瘤的局部免疫监测。
Sci Adv. 2023 Apr 14;9(15):eadd1992. doi: 10.1126/sciadv.add1992. Epub 2023 Apr 12.
6
Transcriptional Factor Repertoire of Breast Cancer in 3D Cell Culture Models.3D细胞培养模型中乳腺癌的转录因子库
Cancers (Basel). 2022 Feb 17;14(4):1023. doi: 10.3390/cancers14041023.
7
Targeting of Evolutionarily Acquired Cancer Cell Phenotype by Exploiting pHi-Metabolic Vulnerabilities.通过利用细胞内pH值代谢弱点靶向进化获得的癌细胞表型
Cancers (Basel). 2020 Dec 28;13(1):64. doi: 10.3390/cancers13010064.
8
Computational models of melanoma.黑色素瘤的计算模型。
Theor Biol Med Model. 2020 May 14;17(1):8. doi: 10.1186/s12976-020-00126-7.
9
Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression.基质反应差异驱动肿瘤细胞进化和前列腺癌进展。
Nat Ecol Evol. 2020 Jun;4(6):870-884. doi: 10.1038/s41559-020-1157-y. Epub 2020 May 11.
10
The double-edged sword role of fibroblasts in the interaction with cancer cells; an agent-based modeling approach.成纤维细胞在与癌细胞相互作用中的双刃剑作用;基于代理的建模方法。
PLoS One. 2020 May 8;15(5):e0232965. doi: 10.1371/journal.pone.0232965. eCollection 2020.

本文引用的文献

1
Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.黑色素瘤的I期试验:将临床前研究结果转化为临床应用的框架。
Eur J Cancer. 2016 Nov;67:213-222. doi: 10.1016/j.ejca.2016.07.024. Epub 2016 Sep 28.
2
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.与成纤维细胞的空间接近度影响乳腺癌细胞的分子特征和治疗敏感性,进而影响临床结果。
Cancer Res. 2016 Nov 15;76(22):6495-6506. doi: 10.1158/0008-5472.CAN-16-1457. Epub 2016 Sep 26.
3
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates.治疗诱导的癌症药物耐药性的数学建模:将癌症机制与人群生存率联系起来。
Sci Rep. 2016 Mar 1;6:22498. doi: 10.1038/srep22498.
4
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.利用进化原理延长乳腺癌临床前模型中的肿瘤控制时间。
Sci Transl Med. 2016 Feb 24;8(327):327ra24. doi: 10.1126/scitranslmed.aad7842.
5
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.多种耐药机制可能源于耐药性癌症持久细胞。
Nat Commun. 2016 Feb 19;7:10690. doi: 10.1038/ncomms10690.
6
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells.微环境异质性对癌细胞耐药性演变的影响
Cancer Inform. 2015 Jul 15;14(Suppl 4):19-31. doi: 10.4137/CIN.S19338. eCollection 2015.
7
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.纤连蛋白诱导消除了BRAF V600E/PTEN缺失的黑色素瘤细胞对BRAF抑制剂的反应。
Oncogene. 2016 Mar 10;35(10):1225-35. doi: 10.1038/onc.2015.188. Epub 2015 Jun 15.
8
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
9
Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes.代谢异质性对肿瘤生长、侵袭及治疗结果的影响。
Cancer Res. 2015 Apr 15;75(8):1567-79. doi: 10.1158/0008-5472.CAN-14-1428.
10
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.活体成像揭示了BRAF抑制如何通过高整合素β1/黏着斑激酶信号产生耐药性微环境。
Cancer Cell. 2015 Apr 13;27(4):574-88. doi: 10.1016/j.ccell.2015.03.008.

整合模型以量化环境介导的耐药性。

Integrating Models to Quantify Environment-Mediated Drug Resistance.

作者信息

Picco Noemi, Sahai Erik, Maini Philip K, Anderson Alexander R A

机构信息

Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, United Kingdom.

出版信息

Cancer Res. 2017 Oct 1;77(19):5409-5418. doi: 10.1158/0008-5472.CAN-17-0835. Epub 2017 Jul 28.

DOI:10.1158/0008-5472.CAN-17-0835
PMID:28754669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8455089/
Abstract

Drug resistance is the single most important driver of cancer treatment failure for modern targeted therapies, and the dialog between tumor and stroma has been shown to modulate the response to molecularly targeted therapies through proliferative and survival signaling. In this work, we investigate interactions between a growing tumor and its surrounding stroma and their role in facilitating the emergence of drug resistance. We used mathematical modeling as a theoretical framework to bridge between experimental models and scales, with the aim of separating intrinsic and extrinsic components of resistance in -mutated melanoma; the model describes tumor-stroma dynamics both with and without treatment. Integration of experimental data into our model revealed significant variation in either the intensity of stromal promotion or intrinsic tissue carrying capacity across animal replicates. .

摘要

耐药性是现代靶向治疗中癌症治疗失败的最重要单一驱动因素,并且肿瘤与基质之间的相互作用已被证明可通过增殖和生存信号来调节对分子靶向治疗的反应。在这项研究中,我们研究了生长中的肿瘤与其周围基质之间的相互作用及其在促进耐药性出现中的作用。我们使用数学建模作为理论框架来连接实验模型和尺度,目的是区分BRAF V600E突变黑色素瘤中耐药性的内在和外在成分;该模型描述了有无治疗情况下的肿瘤-基质动态。将实验数据整合到我们的模型中,发现不同动物重复实验中基质促进强度或内在组织承载能力存在显著差异。